drugset / Trial / NCT01651351

GLASSIA Infusion Rate Study

NCT01651351

Phase 4 Completed 30 enrolled Baxalta now part of Shire
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study was to generate sufficient safety and tolerability information in support of an increase in the infusion rate of intravenous GLASSIA in the prescribing information from 0.04 to 0.2 mL/kg/min.

Timeline

Start
2012-07-31
Primary completion
2013-01-16
Completion
2013-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpha 1-Antitrypsin Protein / enzyme biologic Intravenous